Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

TAS-301

HY-18965

TAS-301

TAS-301 Chemical Structure

TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries

Size Price Stock Quantity
10 mM * 1 mL in DMSO $94 In-stock
5 mg $85 In-stock
10 mg $120 In-stock
50 mg $450 In-stock
100 mg $650 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €92 In-stock
5 mg €83 In-stock
10 mg €118 In-stock
50 mg €441 In-stock
100 mg €637 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: TAS-301
Cat. No.: HY-18965

TAS-301 Data Sheet

  • Pdf Version Network Version

    DataSheet

Related Compound Libraries

Biological Activity of TAS-301

TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries
Target: PKC
in vitro: TAS-301 displays a much more potent effect on neointimal formation than tranilast in the rat balloon injury model in terms of dosage and maximum efficiency and propose a possible mechanism of TAS-301 action based on the results of experiments on the migration and proliferation of vascular SMCs. TAS-301 inhibits the migration of smooth muscle cells (SMCs) stimulated by platelet-derived growth factor-BB, insulin-like growth factor-1 or heparin-binding epidermal growth factor-like growth factor. TAS-301 reduces the proliferation of medial and intimal SMCs at 4 and 8 days, respectively, after the injury. TAS-301 inhibits basic fibroblast growth factor-induced proliferation of SMCs dose dependently. TAS-301 shows a higher inhibitory potency on intimal formation than tranilast due to inhibition of both migration of medial SMCs and proliferation of medial and intimal SMCs.
in vivo: TAS-301 is known to block intimal thickening post balloon injury in rat carotid arteries. It inhibits intimal thickening by blocking Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) and cytoskeletal depolymerization. TAS 301 can also inhibit receptor-regulated influx of calcium in rat vascular smooth muscle cells (VSMCs). Inhibitor of smooth muscle cell migration and proliferation. Blocks voltage-independent calcium influx and downstream PKC signaling. Inhibits neointimal thickening after balloon catheter injury to the rat common carotid artery.

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 357.4 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C23H19NO3
CAS No 193620-69-8
Solvent & Solubility

DMSO:40mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.7980 mL 13.9899 mL 27.9799 mL
5 mM 0.5596 mL 2.7980 mL 5.5960 mL
10 mM 0.2798 mL 1.3990 mL 2.7980 mL

References on TAS-301

Inhibitor Kit

Related PKC Products

  • (-)-Indolactam V

    (-)-Indolactam V (ILV) is a protein kinase C activator, which strongly directs human ES cell-derived definitive endoderm into pancreatic endoderm.

  • CGP60474

    CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics relative to ATP.

  • Chelerythrine Chloride

    Chelerythrine is potent, cell-permeable inhibitor of protein kinase C (IC50 = 660 nM); competitive with respect to the phosphate acceptor and non-competitive with respect to ATP.

  • Enzastaurin

    Enzastaurin (LY317615) is a potent PKC(beta) selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKC(alpha), PKC(gamma) and PKC(epsilon).

  • Go 6983

    Go 6983 is a pan-PKC inhibitor against for PKC(alpha), PKC(beta), PKC(gamma) and PKC(delta) with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKC(zeta) and inactive to PKC(mu).

  • PKC-IN-1

    PKC-IN-1 is a poent PKC beta II inhibitor with Ki of 14.9 nM; compound example H6 from patent WO 2008096260 A1.

  • PKC412

    PKC412(Midostaurin; CGP41231; CGP41251) is a broad spectrum protein kinase inhibitor; inhibits conventional PKC isoforms ((alpha), (beta), (gamma)), PDFR(beta), VEGFR2, Syk, PKC(eta), Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR.

  • Sotrastaurin

    Sotrastaurin(AEB-071) is a potent and selective pan-PKC inhibitor, mostly for PKC(theta) with Ki of 0.22 nM; inactive to PKC(zeta).

  • Staurosporine

    Staurosporine is a prototypical potent ATP-competitive kinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively.